Adult invasive pneumococcal disease in the Republic of Korea: Risk medical conditions and mortality stratified by age group

Int J Infect Dis. 2018 Sep:74:136-144. doi: 10.1016/j.ijid.2018.07.018. Epub 2018 Jul 25.

Abstract

Objectives: This study aimed to characterize the risk factors for mortality in adult patients with invasive pneumococcal disease (IPD) stratified by age groups, after implementation of the national immunization program of 23-valent polysaccharide vaccine (PPSV23) for those aged ≥65 years in the Republic of Korea (ROK).

Methods: Clinical data and pneumococcal isolates from adult patients with IPD (≥18 years of age) were collected prospectively from 20 hospitals through the nationwide surveillance program from March 2013 to October 2015.

Results: A total of 319 patients with IPD were enrolled. Median age was 69 years. Overall in-hospital mortality was 34.2%: 17.1% in those aged 18-49 years, 23.7% in those aged 50-64 years, 33.0% in those aged 65-74 years, and 51.0% in those aged ≥75 years (p<0.001). In particular, early death within 7days of hospitalization accounted for 60.6% (66/109). While old age (≥65 years), higher Pitt bacteremia score (≥4), and bacteremic pneumonia were independently associated with IPD mortality in all age groups, an additional mortality risk factor of immunocompromised status was identified for patients aged 50-64 years. PPSV23 serotypes accounted for 64.4% (122/189) of the pneumococcal isolates serotyped.

Conclusions: This study suggests that vaccine-type IPD continues to place a substantial burden on older adults in the ROK, necessitating an effective vaccination strategy for those at higher risk.

Keywords: Adult; Invasive pneumococcal disease; Mortality; Risk factors.

Publication types

  • Multicenter Study

MeSH terms

  • Adolescent
  • Adult
  • Age Factors
  • Aged
  • Aged, 80 and over
  • Ageism
  • Female
  • Hospitalization
  • Humans
  • Immunization Programs
  • Male
  • Middle Aged
  • Pneumococcal Infections / epidemiology
  • Pneumococcal Infections / immunology
  • Pneumococcal Infections / mortality*
  • Pneumococcal Infections / prevention & control*
  • Pneumococcal Vaccines / administration & dosage*
  • Pneumococcal Vaccines / adverse effects
  • Prospective Studies
  • Republic of Korea / epidemiology
  • Risk Factors
  • Serogroup
  • Sex Factors
  • Streptococcus pneumoniae / classification
  • Streptococcus pneumoniae / genetics
  • Streptococcus pneumoniae / immunology
  • Streptococcus pneumoniae / isolation & purification
  • Vaccination
  • Young Adult

Substances

  • 23-valent pneumococcal capsular polysaccharide vaccine
  • Pneumococcal Vaccines